Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cimzia Pharmacokinetics in Pregnant Women with Chronic Inflammatory Diseases
NCT04163016Phase 1Completed
- Sponsor
- UCB
- Start
- Jun 2020
- Primary completion
- May 2023
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of certolizumab pegol in rheumatoid arthritis (RA), psoriatic arthritis (PsA), Crohn's disease and 2 more, sponsored by UCB. Primary endpoint: Predose and Postdose Plasma Certolizumab Pegol (CZP) Concentrations. Started Jun 2020; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)psoriatic arthritis (PsA)Crohn's diseaseaxial spondyloarthritis (axSpA)plaque psoriasis
Beyond the preview
Go deeper on NCT04163016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04163016.